SOUTH SAN FRANCISCO, Calif., March 27 /PRNewswire-FirstCall/ -- Corgentech Inc. , a biotechnology company, today announced that John P. McLaughlin, the company’s chief executive officer, will present at CIBC World Markets’ Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 4, 2006 at 2:15 p.m., in New York City.
To access the live webcast or the subsequent archived recording, log on to www.corgentech.com and go to the Investors page, and click on Webcasts. Please connect to Corgentech’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Corgentech
Corgentech is a late-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain and inflammation. The company has four drug candidates in clinical development for multiple potential indications, the most advanced of which, ALGRX 3268, has completed Phase 3 clinical trials. Corgentech is based in South San Francisco, CA. For more information on the company, please visit www.corgentech.com.
Corgentech Inc.
CONTACT: Jennifer Cook Williams of Corgentech Inc., +1-650-624-9600, orinvestors@corgentech.com; or Daryl Messinger of WeissComm Partners,+1-415-999-2361, or daryl@weisscommpartners.com, for Corgentech Inc.
Web site: http://www.corgentech.com//
